As of May 27, 2025, Sangamo Therapeutics Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.47, this represents a potential upside of -2569.8%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -2601.9% |
| Potential Upside (10-year) | -2569.8% |
| Discount Rate (WACC) | 6.6% - 9.5% |
Revenue is projected to grow from $58 million in 12-2024 to $83 million by 12-2034, representing a compound annual growth rate of approximately 3.6%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 58 | 67% |
| 12-2025 | 62 | 7% |
| 12-2026 | 63 | 2% |
| 12-2027 | 68 | 6% |
| 12-2028 | 69 | 2% |
| 12-2029 | 70 | 2% |
| 12-2030 | 72 | 2% |
| 12-2031 | 77 | 7% |
| 12-2032 | 79 | 3% |
| 12-2033 | 82 | 3% |
| 12-2034 | 83 | 2% |
Net profit margin is expected to improve from -169% in 12-2024 to -169% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (98) | -169% |
| 12-2025 | (105) | -169% |
| 12-2026 | (108) | -169% |
| 12-2027 | (114) | -169% |
| 12-2028 | (117) | -169% |
| 12-2029 | (119) | -169% |
| 12-2030 | (121) | -169% |
| 12-2031 | (130) | -169% |
| 12-2032 | (134) | -169% |
| 12-2033 | (138) | -169% |
| 12-2034 | (141) | -169% |
with a 5-year average of $16 million. Projected CapEx is expected to maintain at approximately 13% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 15 |
| 12-2026 | 12 |
| 12-2027 | 9 |
| 12-2028 | 7 |
| 12-2029 | 9 |
| 12-2030 | 9 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 6 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 9M/2025 | (73) | (0) | 6 | 12 | (90) |
| 2026 | (103) | (0) | 8 | (0) | (110) |
| 2027 | (112) | (0) | 9 | 0 | (121) |
| 2028 | (117) | (0) | 9 | 0 | (126) |
| 2029 | (118) | (0) | 9 | (0) | (127) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -2601.9% |
| 10-Year DCF (Growth) | 0.00 | -2569.8% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Sangamo Therapeutics Inc (SGMO) a buy or a sell? Sangamo Therapeutics Inc is definitely a sell. Based on our DCF analysis, Sangamo Therapeutics Inc (SGMO) appears to be overvalued with upside potential of -2569.8%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.47.